Metastatic Castrate Resistant Prostate Cancer Mcrpc clinical trials

Explore recruiting metastatic castrate resistant prostate cancer mcrpc clinical trials.

Recruiting metastatic castrate resistant prostate cancer mcrpc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Castrate Resistant Prostate Cancer Mcrpc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer

Italy, Germany, Poland, France, Denmark, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Spain, Poland, Netherlands, Italy, Germany, Ireland +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

(20510) A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of androgen receptor pathway inhibitor (ARPI) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of ARPI

Italy, Poland, Lithuania, Austria, Hungary, France +4 more

Therapeutic use (Phase IV) EU CTIS Study details

Metastatic Castrate Resistant Prostate Cancer Mcrpc trials by city

Metastatic Castrate Resistant Prostate Cancer Mcrpc in Toronto Metastatic Castrate Resistant Prostate Cancer Mcrpc in Vancouver Metastatic Castrate Resistant Prostate Cancer Mcrpc in Montreal Metastatic Castrate Resistant Prostate Cancer Mcrpc in Calgary Metastatic Castrate Resistant Prostate Cancer Mcrpc in Edmonton Metastatic Castrate Resistant Prostate Cancer Mcrpc in Ottawa Metastatic Castrate Resistant Prostate Cancer Mcrpc in Winnipeg Metastatic Castrate Resistant Prostate Cancer Mcrpc in Quebec City Metastatic Castrate Resistant Prostate Cancer Mcrpc in Hamilton Metastatic Castrate Resistant Prostate Cancer Mcrpc in Kitchener Metastatic Castrate Resistant Prostate Cancer Mcrpc in London Metastatic Castrate Resistant Prostate Cancer Mcrpc in Halifax Metastatic Castrate Resistant Prostate Cancer Mcrpc in New York Metastatic Castrate Resistant Prostate Cancer Mcrpc in Los Angeles Metastatic Castrate Resistant Prostate Cancer Mcrpc in Chicago Metastatic Castrate Resistant Prostate Cancer Mcrpc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease